---
schema_version: "secwatch.filing_event.v1"
accession: "0001799191-23-000012"
form_type: "8-K"
ticker: "TOI"
cik: "0001799191"
company_name: "Oncology Institute, Inc."
filed_at: "2023-06-12T23:59:59+00:00"
generated_at: "2026-06-14T03:08:18.985364+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Oncology Institute CEO Brad Hively steps down, President Daniel Virnich promoted to CEO

## Summary
- Brad Hively resigns as CEO effective June 30, 2023; will become Vice Chairman of the Board.
- Daniel Virnich, current President, appointed CEO effective June 30, 2023.
- Hively's resignation not due to any disagreement; severance includes salary continuation, 50% of 2023 bonus, and RSU vesting through June 2024.
- Virnich joined TOI in 2020 as COO, promoted to President; previously at DaVita and TeamHealth.

## SEC filing metadata
- accession: 0001799191-23-000012
- form_type: 8-K
- ticker: TOI
- cik: 0001799191
- company_name: Oncology Institute, Inc.
- filed_at: 2023-06-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799191/000179919123000012/0001799191-23-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799191/000179919123000012/toi-20230611.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001799191-23-000012
- JSON: https://secwatch.observer/filing/0001799191-23-000012.json
- Plain text: https://secwatch.observer/filing/0001799191-23-000012.txt

## Key facts
- Executive change
  Brad Hively was appointed as Vice Chair of the Board at Oncology Institute, Inc..
  - Action: appointed
  - Role: Vice Chair of the Board
  source text: Additionally, the Board appointed Mr. Hively to serve as Vice Chair of the Board at the Effective Time
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799191/000179919123000012/0001799191-23-000012-index.htm
- Executive change
  Brad Hively resigned as Chief Executive Officer at Oncology Institute, Inc..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: On June 11, 2023, Brad Hively provided notice of his resignation as Chief Executive Officer of The Oncology Institute, Inc. (the “Company”), effective June 30, 2023 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799191/000179919123000012/0001799191-23-000012-index.htm
- Executive change
  Daniel Virnich was appointed as Chief Executive Officer at Oncology Institute, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: Effective as of June 30, 2023, the Board appointed Daniel Virnich, the Company’s current President, as Chief Executive Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799191/000179919123000012/0001799191-23-000012-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.